Marksans Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Marksans Pharma is poised for stable revenue growth, supported by management's strategic focus on expanding its footprint in regulated markets and leveraging its underutilized Teva facility. The company has successfully crossed the INR3,000 crore revenue milestone and aims for INR4,000 crores by FY28, driven by aggressive product filings and potential M&A activities. While near-term cost pressures from raw material inflation and geopolitical risks are acknowledged, management's emphasis on operational efficiencies and a strong cash position mitigates margin concerns. Vista's financial outlook reflects these developments, projecting improving margins and a fair valuation aligned with intrinsic value. The macro environment in India, characterized by robust growth and favorable liquidity conditions, further supports Marksans' expansion strategy. Over the next 12-24 months, key opportunities include capturing the OTC store brand market in the US and UK, while watchpoints include raw material supply constraints and geopolitical risks that could impact production costs. Overall, Marksans is well-positioned to capitalize on emerging opportunities in the Pharma APIs and CRAMS sector, with a constructive investor sentiment underpinning its outlook
Why We Like This Stock
- Management's focus on expanding into regulated markets and leveraging the Teva facility enhances revenue growth potential
- Strong cash position supports strategic acquisitions and operational efficiencies, mitigating near-term cost pressures
- Positive macroeconomic conditions in India bolster the company's growth trajectory
Things To Watch Out For
- Raw material inflation and geopolitical risks pose challenges to margin stability
- Competitive pricing pressures in the Pharma APIs and CRAMS sector may impact profitability
- Supply chain constraints could hinder production capabilities and growth targets
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,177 | 2,623 | 2,951 | 3,321 | 3,767 |
| Profit Before Tax (Cr.) | 424 | 503 | 561 | 791 | 850 |
| PBT Margin | 19.5% | 19.2% | 1901.1% | 23.8% | 22.6% |
| Net Profit (Cr.) | 310 | 377 | 420 | 593 | 635 |
| Earnings Per Share | 6.8 | 8.3 | 9.2 | 13.0 | 14.0 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Choice Equity | ► Hold | 290 | 29-May-2026 |
Company Overview
Show Company Profile
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.